| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 612 | 2020 |
| Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma BP Fairfax, CA Taylor, RA Watson, I Nassiri, S Danielli, H Fang, EA Mahé, ... Nature medicine 26 (2), 193-199, 2020 | 245 | 2020 |
| Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma MR Middleton, C McAlpine, VK Woodcock, P Corrie, JR Infante, ... Clinical Cancer Research 26 (22), 5869-5878, 2020 | 157 | 2020 |
| First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due … S Postel-Vinay, K Herbschleb, C Massard, V Woodcock, JC Soria, ... European Journal of Cancer 109, 103-110, 2019 | 100 | 2019 |
| Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis P Zarifkar, A Kamath, C Robinson, N Morgulchik, SFH Shah, TKM Cheng, ... Clinical Oncology 33 (3), e180-e191, 2021 | 77 | 2021 |
| Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19 C Várnai, C Palles, R Arnold, HM Curley, K Purshouse, VWT Cheng, ... JAMA network open 5 (2), e220130-e220130, 2022 | 49 | 2022 |
| IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma CA Taylor, RA Watson, O Tong, W Ye, I Nassiri, JJ Gilchrist, ... Nature Medicine 28 (12), 2592-2600, 2022 | 25 | 2022 |
| First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies S Postel-Vinay, K Herbschleb, C Massard, V Woodcock, M Ocker, ... European Journal of Cancer 1 (69), S7-S8, 2016 | 19 | 2016 |
| A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC). VK Woodcock, K Purshouse, C Butcher, C Haddon, G Verrall, L Elhussein, ... Journal of Clinical Oncology 37 (7_suppl), 406-406, 2019 | 10 | 2019 |
| A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424 VK Woodcock, S Clive, RH Wilson, VM Coyle, MRL Stratford, LK Folkes, ... British Journal of Cancer 118 (6), 770-776, 2018 | 10 | 2018 |
| Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma HE Fayed, VK Woodcock, J Grayez Case Reports 2013, bcr2013009350, 2013 | 7 | 2013 |
| Variability in body temperature in healthy adults and in patients receiving chemotherapy: prospective observational cohort study JS Frazer, GE Barnes, V Woodcock, E Flanagan, T Littlewood, RJ Stevens, ... Journal of Medical Engineering & Technology 43 (5), 323-333, 2019 | 5 | 2019 |
| PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer VK Woodcock, JL Chen, K Purshouse, C Butcher, L Collins, C Haddon, ... BJUI compass 4 (3), 322-330, 2023 | 3 | 2023 |
| Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma. MR Middleton, NM Steven, TRJ Evans, JR Infante, O Hamid, ... Journal of Clinical Oncology 37 (15_suppl), 9523-9523, 2019 | 3 | 2019 |
| Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma A Shoushtari, M Middleton, N Stevens, T Evans, J Infante, M Sznol, ... | 3 | 2019 |
| PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer SP Blagden, A Sukumaran, L Spiers, VK Woodcock, A Lipplaa, S Nicum, ... Annals of Oncology 28, v345, 2017 | 3 | 2017 |
| Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors E Ghazaly, VK Woodcock, P Spilipoulou, L Spiers, J Moschandreas, ... Annals of Oncology 28, v128, 2017 | 3 | 2017 |
| Semaphorin 3A induces cytoskeletal paralysis in tumor-specific CD8+ T cells MB Barnkob, YS Michaels, V André, PS Macklin, U Gileadi, S Valvo, ... BioRxiv, 849083, 2019 | 2 | 2019 |
| Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma. MR Middleton, NM Steven, TRJ Evans, JR Infante, M Sznol, O Hamid, ... Journal of Clinical Oncology 37 (15_suppl), 9530-9530, 2019 | 2 | 2019 |
| A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC) K Purshouse, VK Woodcock, C Butcher, C Haddon, G Verrall, L Elhussein, ... European Urology Supplements 18 (1), e771, 2019 | 1 | 2019 |
